Votrient 400mg (Pazopanib)

Votrient 400mg (Pazopanib) – Comprehensive Product Description

Brand Name: Votrient
Generic Name: Pazopanib
Strength: 400 mg
Form: Tablets
Therapeutic Class: Tyrosine Kinase Inhibitor (TKI)
Route of Administration: Oral
Prescription Required: Yes

What is Votrient 400mg?

Votrient 400 mg is an oral anticancer drug that includes Pazopanib, the most potent and effective tyrosine kinase inhibitor (TKI). It is a drug that blocks various receptor tyrosine-kinase kinases that are involved in angiogenesis and tumor growth. (Formation of blood vessels). In blocking these pathways, Votrient assists in slowing down or even stopping the development of some types of cancers.

The drug is used primarily for the treatment of the advanced stage of renal cell cancer (RCC) and advanced soft tissue tumors (STS) after prior treatment. Votrient offers a specific treatment that alters the flow of blood to tumors, which limits their expansion and growth.

Indications (Uses)

Votrient 400 mg is prescribed for:

• Advanced or metastatic renal cell carcinoma (RCC), either treatment-naïve or following cytokine therapy
• Advanced soft tissue sarcoma (STS) for patients who’ve received prior chemotherapy
• The other causes could be considered in accordance with the discretion of the physician, as well as ongoing research

Mechanism of Action

Pazopanib is a multi-targeted tyrosine inhibitor of kinases that inhibits the activities of a variety of receptors. This includes:

• Vascular Endothelial Growth Factor Receptors (VEGFR-1, VEGFR-2, VEGFR-3): The receptors stimulate angiogenesis that tumors utilize to get the flow of blood and to gain nutrients.
• Platelet-Derived Growth Factor Receptors (PDGFR-α and PDGFR-β): It is involved in the growth of tumors and maintaining blood vessels.
• c-Kit (Stem Cell Factor Receptor): A key factor in the growth of tumor cells in certain cancers.

Inhibiting these receptors, Votrient reduces angiogenesis in tumors and cell proliferation, ultimately hindering the progression of tumors.

Dosage and Administration

• Recommended Dose: The standard starting dose of Votrient will be 800 mg taken orally each day. The tablets of 400 mg are usually prescribed to reach this daily total dose (for instance, two tablets of 400 mg).
• Administration:
  • Drink a glass of water at least an hour before or two hours after eating for optimal absorption.
  • Drink the tablets completely in water. Do not chew, crush, or split.
• Dose Adjustments:
  • Modifications to dosages may be necessary depending on the individual’s tolerance as well as adverse reactions.
  • In the event of serious negative side effects, a dosage reduction or temporary interruption could be required.
• Missed Dose: If a dose has been missed, you should take it as fast as you remember, unless it’s close to the time of your next dosage. Never double your dose.

Benefits of Votrient 400 mg

• A targeted cancer treatment specifically targeting the inhibition of the blood supply to the tumor and its growth
• Highly effective for treating renal cell cancers that are advanced and prolonging the time to progression-free survival
• It is a treatment option available for patients with advanced soft-tissue sarcoma for whom chemotherapy has not worked.
• Oral administration is convenient compared to intravenous chemotherapy
• It is well-studied and has established doses and a safety profile for patients with cancer.
• It can be used in conjunction with other treatments with a specialist

Side Effects

Similar to many cancer treatments, Votrient 400 mg may produce side effects that range from moderate to extreme.

Common Side Effects:

• Diarrhea
• Hypertension (high blood pressure)
• Hair color changes (hair depigmentation)
• Nausea and vomiting
• Fatigue
• Headache
• Elevated liver enzymes

Serious Side Effects:

• Hepatotoxicity (liver damage) – requires regular liver function monitoring
• Cardiac issues such as QT prolongation and heart failure
• Hemorrhage (bleeding)
• Gastrointestinal perforation or fistula
• Thrombotic events (blood clots)
• Severe hypertension requiring intervention
• Proteinuria (protein in urine)
• Hypothyroidism

The patient should notify the doctor of any symptoms that are unusual, such as extreme abdominal pain, jaundice, chest pain, or breathing problems, immediately.

Warnings and Precautions

• Liver Toxicity: The regular liver function tests (LFTs) are required for treatment to avoid the possibility of liver toxicity.
• Hypertension: Check blood pressure frequently and treat hypertension quickly.
• Cardiac Monitoring: Heart patients with a preexisting condition need to be monitored closely.
• Bleeding Risk: Be cautious when using this medication in patients who are at risk of bleeding or who are taking anticoagulants.
• Gastrointestinal Risk: Examine for any signs that suggest GI perforation.
• Pregnancy and Lactation: Votrient is not recommended in pregnancy. Effective contraception should be utilized both during and following treatment. The safety of breastfeeding is not known.
• Drug Interactions: Beware of concurrent use with highly potent CYP3A4 inhibitors and inducers since they may affect the levels of Pazopanib.

Contraindications

• A known hypersensitivity reaction to Pazopanib, as well as any other constituents
• Severe liver impairment
• Pregnancy and breastfeeding
• Use in conjunction with powerful CYP3A4 inducers or inhibitors (may necessitate dose adjustments or disabling)

Drug Interactions

• CYP3A4 Inhibitors: Ketoconazole, clarithromycin, ritonavir may increase Pazopanib levels, increasing toxicity risk.
• CYP3A4 Inducers: The combination of phenytoin and rifampin could lower Pazopanib’s efficiency.
• Other QT-Prolonging Drugs: Use in combination increases the risk of heart attacks.
• Anticoagulants: Risk of bleeding may increase. Be sure to monitor it carefully.
• Be sure to inform your healthcare provider of any medication, even herbal supplements.

Storage Instructions

• Keep the temperature of your room at a controlled level (20°C to 25°C or 68°F to 77°F).
• Guard against light and moisture.
• Be sure to keep away from children.
• Do not use after the expiration date.

Patient Counseling Information

• Consume Votrient when you are on a full stomach for at least 1 hour before or 2 hours following meals.
• Take tablets whole, but don’t crush or chew.
• Check blood pressure frequently during treatment.
• Be aware of any liver issues (yellowing eyes or skin or bloody urine), abnormal bleeding, chest pain, or a severe feeling of fatigue right away.
• Do not drink grapefruit juice or grapefruit, as they can cause a reaction with the medication.
• Utilize effective contraception to avoid pregnancies during treatment and afterwards.
• Follow-ups are scheduled for all follow-ups as well as test results in the laboratory.

Frequently Asked Questions (FAQs)

Q1: How long does it take for Votrient to work?

A1: The treatment response is different; it is possible that the tumor’s growth slows within several weeks or months after beginning treatment.

Q2: Can I eat while taking Votrient?

A2: It is recommended to take it on an empty stomach for maximum absorption.

Q3: What should I do if I miss a dose?

A3: Make sure to take the missed dose as quickly as you can until it’s time to take another dose. Don’t double-up.

Q4: Are there any foods or drugs I should avoid?

A4: Do not drink grapefruit or grapefruit juice. Inform your physician about any medications.

Q5: Can Votrient cure cancer?

A5: Votrient can control and stop the growth of cancer, but it’s not an effective treatment.

Conclusion

Votrient 400 mg (Pazopanib) is an effective targeted treatment that provides a therapeutic choice for renal cell carcinomas and soft tissue tumors. By blocking the key pathways that are involved in tumor growth and angiogenesis, the drug helps to manage the progression of cancer effectively. It is also convenient to administer via oral administration; careful medical supervision is essential in order to detect potential side effects and to ensure that the treatment is effective.